Editas Medicine (EDIT) AI Stock Analysis

• Market Cap: $185.01M
• Dividend Yield: N/A
• Average Volume (3M): 2.68M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.40
• Revenue Growth: -48.37%
• EPS Growth: -44.70%
• Country: US
• Employees: 246
• Sector: Healthcare
• Sector Strength: 38
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 83,712,860
• 10 Day Avg. Volume: 1,797,590
• 30 Day Avg. Volume: 2,682,433
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: -0.51
• Enterprise Value/Revenue: -2.61
• Enterprise Value/Gross Profit: -2.97
• Enterprise Value/Ebitda: 0.38
• 1Y Price Target: $3.03
• Price Target Upside: 37.10% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 11

• Rating: 51 Neutral
• Price Target: $2.00 ▼(-9.50% Downside)

Editas Medicine's overall stock score reflects a challenging financial position typical of early-stage biotech companies, with significant reliance on external funding. However, recent advancements in gene editing provide a positive outlook for future growth. Technical indicators suggest caution, but potential for a rebound exists. Valuation remains a concern due to ongoing losses.

Positive Factors

Innovation and Preclinical Success

Editas has shown highly promising preclinical data from their Sickle Cell Disease and liver programs, indicating potential for future clinical success.

Technology and Efficacy

Editas's therapy has achieved an editing rate far exceeding the therapeutic threshold, viewed as a risk-mitigating feature before clinical development.

Negative Factors

Financial Performance

Editas reported a net loss of $0.92 per share, which was larger than the prior estimate of a net loss of $0.55 per share.

Legal and Patent Issues

There is increasing uncertainty in the Cas9 patent interference case as the appellate court has instructed PTAB to reconsider its decision.

Editas Medicine Business Overview & Revenue Model

Company Description

Editas Medicine (EDIT) is a biotechnology company focused on developing transformative genomic medicines using its proprietary CRISPR gene-editing technology. The company operates primarily in the field of genetic medicine, targeting diseases caused by genetic mutations, including inherited retinal diseases and other serious conditions. Editas aims to leverage its innovative platform to create therapies that can correct the underlying genetic causes of diseases, with a pipeline that includes both in vivo and ex vivo applications of CRISPR technology.

How the Company Makes Money

Editas Medicine generates revenue through a combination of product development agreements, collaborations, and potential future sales of therapies that successfully pass through clinical trials. The company has established partnerships with various pharmaceutical companies and research institutions, which often provide funding in exchange for rights to co-develop or commercialize specific therapies. Additionally, Editas may receive milestone payments and royalties based on the commercial success of its products. The company's financial performance is also influenced by grants and investments aimed at supporting its research and development initiatives.

Editas Medicine Financial Statement Overview

Summary

Editas Medicine faces significant financial challenges typical of biotech firms in the R&D phase. The lack of revenue growth and persistent losses indicate difficulties in transitioning to a commercially viable model. While the balance sheet is supported by strong cash reserves, the continuous negative cash flow suggests an ongoing reliance on external funding.

Income Statement

Editas Medicine has shown a volatile revenue trajectory with a significant drop to zero revenue in 2024 from previous levels. The company has consistently reported negative net income, leading to negative profit margins. This indicates challenges in achieving profitability, common in the biotech industry, which often requires substantial R&D investments without immediate revenue.

Balance Sheet

The company's balance sheet exhibits moderate financial health with a significant cash reserve relative to its total assets. The debt-to-equity ratio is low, suggesting conservative use of debt. However, the continuous decline in stockholders' equity indicates erosion of shareholder value, which is a concern.

Cash Flow

Editas Medicine has consistently faced negative operating and free cash flows, reflecting operational struggles and high cash burn. Although there are instances of positive financing cash flows, this is likely due to capital raises rather than operational efficiency, posing a risk to long-term sustainability.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	32.31M	78.12M	19.71M	25.54M	90.73M
Gross Profit	26.50M	-99.53M	13.38M	20.49M	-67.26M
EBITDA	-231.28M	-163.12M	-219.61M	-188.09M	-130.88M
Net Income	-237.09M	-153.22M	-204.35M	-185.11M	-109.41M
Balance Sheet
Total Assets	341.59M	499.15M	514.32M	677.48M	572.60M
Cash, Cash Equivalents and Short-Term Investments	269.91M	323.11M	437.37M	619.91M	511.77M
Total Debt	35.03M	36.54M	43.95M	26.38M	26.14M
Total Liabilities	207.31M	150.06M	153.64M	123.84M	179.02M
Stockholders Equity	134.27M	349.10M	360.68M	553.64M	393.59M
Cash Flow
Free Cash Flow	-219.11M	-136.90M	-181.47M	-171.78M	-187.00M
Operating Cash Flow	-210.28M	-132.18M	-177.35M	-163.80M	-179.84M
Investing Cash Flow	162.15M	-3.73M	114.07M	-54.47M	-140.52M
Financing Cash Flow	56.03M	118.04M	1.28M	282.11M	224.12M

Editas Medicine Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.21
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EDIT, the sentiment is Negative. The current price of 2.21 is below the 20-day moving average (MA) of 2.79, below the 50-day MA of 2.45, and above the 200-day MA of 1.92, indicating a neutral trend. The MACD of -0.03 indicates Positive momentum. The RSI at 37.83 is Neutral, neither overbought nor oversold. The STOCH value of 11.16 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for EDIT.

Editas Medicine Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CLLS	64 Neutral	$199.02M	―	-48.26%	―	333.77%	―
Sector *	60 Neutral	HK$18.08B	4.77	-4.00%	3.35%	9.59%	-23.62%
EDIT	51 Neutral	$185.01M	―	-140.82%	―	-48.37%	-44.70%
NKTX	39 Underperform	$140.50M	―	-26.10%	―	―	35.73%
RAPT	39 Underperform	$162.24M	―	-77.83%	―	―	43.16%
CTNM	39 Underperform	$167.39M	―	-29.24%	―	―	-125.92%
NMRA	33 Underperform	$236.44M	―	-89.37%	―	―	9.84%

Editas Medicine Corporate Events

Editas Medicine Unveils Promising Gene Editing Data

On June 12, 2025, Editas Medicine announced new in vivo data at the European Hematology Association 2025 Congress, demonstrating significant advancements in gene editing for sickle cell disease and beta thalassemia. The study showed that a single dose of their proprietary targeted lipid nanoparticle (tLNP) in non-human primates achieved a 58% mean on-target editing level in the HBG1/2 promoter region of hematopoietic stem cells, surpassing the therapeutic threshold. This development supports the potential of Editas’ approach to provide a novel treatment for these conditions, with favorable biodistribution and minimal liver targeting, enhancing the company’s position in the gene editing industry.

The most recent analyst rating on (EDIT) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Editas Medicine stock, see the EDIT Stock Forecast page.

Editas Medicine Stockholders Approve Key Amendments

At the 2025 Annual Meeting of Stockholders held on May 29, Editas Medicine, Inc.’s stockholders approved significant amendments to the company’s 2015 Stock Incentive Plan, extending its term and eliminating the ‘evergreen’ provision, among other changes. Additionally, stockholders approved an increase in the number of authorized shares of the company’s capital stock, which could impact the company’s ability to raise capital and expand its operations.

The most recent analyst rating on (EDIT) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Editas Medicine stock, see the EDIT Stock Forecast page.

Editas Medicine Unveils Promising Gene Editing Data

On May 14, 2025, Editas Medicine announced new in vivo data showcasing the potential of their gene upregulation strategy in hematopoietic stem cells (HSCs) at the American Society of Gene and Cell Therapy Annual Meeting. The data demonstrated that a single dose of their proprietary targeted lipid nanoparticle (tLNP) achieved therapeutically relevant levels of HBG1/2 promoter editing in both humanized mice and non-human primates, exceeding the predicted therapeutic threshold. This approach, which targets HBG1/2 promoters to upregulate fetal hemoglobin, is in pre-clinical development for treating sickle cell disease and beta thalassemia, potentially positioning Editas Medicine as a leader in in vivo gene editing therapies.

The most recent analyst rating on (EDIT) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Editas Medicine stock, see the EDIT Stock Forecast page.

Editas Medicine Unveils In Vivo Gene Editing Data

On May 13, 2025, Editas Medicine announced in vivo proof of concept data for a liver target at the American Society of Gene and Cell Therapy Annual Meeting. The study demonstrated significant gene editing and protein upregulation in mice and monkeys, indicating potential for a first-in-class treatment for liver diseases. This advancement positions Editas as a leader in gene editing therapies, with plans to reveal more details about the target and development candidate later in the year.

The most recent analyst rating on (EDIT) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Editas Medicine stock, see the EDIT Stock Forecast page.